344 related articles for article (PubMed ID: 19216070)
1. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
[TBL] [Abstract][Full Text] [Related]
2. Progress in the development of childhood cancer therapy.
Garolla A; Pizzato C; Ferlin A; Carli MO; Selice R; Foresta C
Reprod Toxicol; 2006 Aug; 22(2):126-32. PubMed ID: 16781110
[TBL] [Abstract][Full Text] [Related]
3. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors.
van Casteren NJ; van der Linden GH; Hakvoort-Cammel FG; Hählen K; Dohle GR; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2009 Jan; 52(1):108-12. PubMed ID: 18819129
[TBL] [Abstract][Full Text] [Related]
4. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
5. Does ifosfamide affect gonadal function?
Williams D; Crofton PM; Levitt G
Pediatr Blood Cancer; 2008 Feb; 50(2):347-51. PubMed ID: 17973323
[TBL] [Abstract][Full Text] [Related]
6. [Delayed effect of cyclophosphamide on testicular function after treatment of nephrotic syndrome in childhood].
Bogdanović R; Cvorić A; Banićević M; Zdravković D; Nikolić V; Ognjanović M
Srp Arh Celok Lek; 1990; 118(5-6):235-42. PubMed ID: 2127483
[TBL] [Abstract][Full Text] [Related]
7. Dose-Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma.
Servitzoglou M; De Vathaire F; Oberlin O; Patte C; Thomas-Teinturier C
Pediatr Hematol Oncol; 2015; 32(8):613-23. PubMed ID: 26561347
[TBL] [Abstract][Full Text] [Related]
8. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence.
Ishiguro H; Yasuda Y; Tomita Y; Shinagawa T; Shimizu T; Morimoto T; Hattori K; Matsumoto M; Inoue H; Yabe H; Yabe M; Shinohara O; Kato S
Bone Marrow Transplant; 2007 Apr; 39(8):483-90. PubMed ID: 17334386
[TBL] [Abstract][Full Text] [Related]
9. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
11. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood.
Kenney LB; Laufer MR; Grant FD; Grier H; Diller L
Cancer; 2001 Feb; 91(3):613-21. PubMed ID: 11169946
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide vs cyclophosphamide in cancer therapy.
Weiss RB
Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
[TBL] [Abstract][Full Text] [Related]
14. [The evaluation of gonadal function in postpubertal patients treated for cryptorchism in childhood].
Crespo Chozas D; Alonso Blanco M; Yturriaga Matarranz R; Barrio Castellanos R
An Esp Pediatr; 1999 Jan; 50(1):33-8. PubMed ID: 10083640
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
16. Influence of age upon Ifosfamide-induced nephrotoxicity.
McCune JS; Friedman DL; Schuetze S; Blough D; Magbulos M; Hawkins DS
Pediatr Blood Cancer; 2004 May; 42(5):427-32. PubMed ID: 15049014
[TBL] [Abstract][Full Text] [Related]
17. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide in the treatment of breast cancer.
Overmoyer BA
Semin Oncol; 1996 Jun; 23(3 Suppl 6):38-41. PubMed ID: 8677447
[TBL] [Abstract][Full Text] [Related]
19. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
20. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
